A detailed history of Huntleigh Advisors, Inc. transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Huntleigh Advisors, Inc. holds 113,772 shares of ADMA stock, worth $1.66 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares
113,772
Previous 109,616 3.79%
Holding current value
$1.66 Million
Previous $2.17 Billion 4.74%
% of portfolio
0.4%
Previous 0.51%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 29, 2025

BUY
$17.6 - $24.51 $73,145 - $101,863
4,156 Added 3.79%
113,772 $2.07 Billion
Q1 2025

Apr 29, 2025

BUY
$15.44 - $20.61 $149,567 - $199,649
9,687 Added 9.69%
109,616 $2.17 Billion
Q4 2024

Apr 29, 2025

BUY
$15.62 - $22.62 $1.56 Million - $2.26 Million
99,929 New
99,929 $1.71 Billion

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $2.86B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Huntleigh Advisors, Inc. Portfolio

Follow Huntleigh Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntleigh Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Huntleigh Advisors, Inc. with notifications on news.